Merck Receives FDA Approval for Keytruda in Frontline Endometrial Cancer

Merck today announced that the FDA has approved KEYTRUDA (pembrolizumab) in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the first-line treatment of adults with advanced or recurrent endometrial carcinoma. In the Phase 3 KEYNOTE-868/NRG-GY018 trial, KEYTRUDA plus chemotherapy demonstrated a statistically significant improvement in progression-free survival compared to chemotherapy alone regardless of MSI status. The median PFS was 13.1 months for KEYTRUDA plus chemotherapy versus 8.7 months for chemotherapy alone in the overall population. This approval provides patients with endometrial cancer a new first-line treatment option.